Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
WGS
SellSinkerGeneDx Holdings Corp. · Healthcare · United States · $2.6B · Avg Vol: $57M/d
COMPANY DESCRIPTION
GeneDx Holdings Corp. is a leader in clinical genomics, specializing in exome and genome sequencing to diagnose rare diseases and pediatric disorders. The company's competitive moat is anchored by its massive proprietary genomic database and advanced clinical interpretation engine. It operates as a premier diagnostic player at the forefront of precision medicine.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 234.7M | 202.6M | 305.4M | 427.5M | 22.1% | 454.4M | 481.6M | 598.6M | 18.3% |
| EPS | -21.33 | -7.23 | -1.94 | -0.73 | — | -3.63 | — | — | — |
| Shares | 29.7M | 26.0M | 28.0M | 29.2M | -1.5% | 29.8M | — | — | — |
| Debt | 77.1M | 119.3M | 117.4M | 113.2M | 13.6% | 167.4M | — | — | — |
| Equity | 253.7M | 228.0M | 245.2M | 308.2M | 6.7% | — | — | — | — |
| Op CF | -319.2M | -180.1M | -28.5M | 33.3M | — | -48.7M | — | — | — |
| Inv CF | -141.3M | -43.7M | -30.1M | -61.5M | — | — | — | — | — |
| Fin CF | 197.3M | 186.2M | 44.2M | 48.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WGS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| WGS | GeneDx Holdings Corp.(you) | $2.6B | 24 | Sell |
| PSNL | Personalis, Inc. | $1.8B | 24 | Sell |
| GRAL | GRAIL, Inc. | $3.6B | 28 | Sell |
| FRNM | Freenome, Inc. | $1.6B | 18 | Strong Sell |
| ADPT | Adaptive Biotechnologies Corporation | $4.0B | 38 | Hold |
| NEO | NeoGenomics, Inc. | $2.3B | 47 | Hold |
| RDNT | RadNet, Inc. | $5.9B | 34 | Sell |
| OPK | OPKO Health, Inc. | $1.1B | 38 | Hold |
| CSTL | Castle Biosciences, Inc. | $1.0B | 39 | Hold |
| MYGN | Myriad Genetics, Inc. | $302M | 21 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%